New concepts in the management of dyslipidaemia
Recently, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) published a consensus paper giving guidance on the definition and management of statin-associated muscle symptoms (SAMS), as well as the use of proprotein convertase subtilisin kexin 9 (PCSK9) inhibit...
Main Authors: | Baris Gencer, Nicolas Rodondi, Francois Mach |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2016-11-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/2245 |
Similar Items
-
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01) -
Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention – Journey from hospital to cardiac rehabilitation
by: David Rott, et al.
Published: (2022-12-01) -
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01) -
Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
by: Markus Mohaupt
Published: (2016-07-01) -
Use and role of monoclonal antibodies and other biologics in preventive cardiology
by: Baris Gencer, et al.
Published: (2015-11-01)